Significant advances in understanding the signaling pathways that drive pulmonary fibrosis (PF) are reshaping how clinicians diagnose and treat idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). With the first novel-mechanism therapy in more than a decade approved in 2025 and multiple emerging agents on the horizon, pulmonology is entering a new era of targeted care. These rapid developments, paired with updated PF classification criteria, make staying current essential for all clinicians who manage fibrotic lung disease. Join PF expert Rachel N. Criner, MD for a CME-accredited, case-based challenge that brings these shifts to life. Explore clinical case scenarios, compare new and emerging therapies, and strengthen your ability to optimize treatment in an evolving PF landscape.